Phase I study of peptide receptor radionuclide therapy with [111In-DTPA0]octreotide: The rotterdam experience

Valkema, Roelf; de Jong, Marion; Bakker, Willem H.; Breeman, Wout A.P.; Kooij, Peter P.M.; Lugtenburg, Pieternella J.; de Jong, Frank H.; Christiansen, Arjan; Kam, Boen L.R.; de Herder, Wouter W.; Stridsberg, Mats; Lindemans, Jan; Ensing, Geert; Krenning, Eric P.

doi:10.1053/snuc/2002.31025

« Previous Next »Seminars in Nuclear Medicine
Volume 32, Issue 2 , Pages 110-122, April 2002

Phase I study of peptide receptor radionuclide therapy with [¹¹¹In-DTPA⁰]octreotide: The rotterdam experience

Roelf Valkema
- Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
- Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
- Department of Hetology, Erasmus MC, Rotterdam, The Netherlands
- Department of Clinical Chemistry, Erasmus MC, Rotterdam, The Netherlands
- Department of Medical Sciences, University Hospital, Uppsala, Sweden
- Department of Tyco Healthcare, Petten, The Netherlands
Marion de Jong
- Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
- Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
- Department of Hetology, Erasmus MC, Rotterdam, The Netherlands
- Department of Clinical Chemistry, Erasmus MC, Rotterdam, The Netherlands
- Department of Medical Sciences, University Hospital, Uppsala, Sweden
- Department of Tyco Healthcare, Petten, The Netherlands
Willem H. Bakker
- Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
- Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
- Department of Hetology, Erasmus MC, Rotterdam, The Netherlands
- Department of Clinical Chemistry, Erasmus MC, Rotterdam, The Netherlands
- Department of Medical Sciences, University Hospital, Uppsala, Sweden
- Department of Tyco Healthcare, Petten, The Netherlands
Wout A.P. Breeman
- Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
- Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
- Department of Hetology, Erasmus MC, Rotterdam, The Netherlands
- Department of Clinical Chemistry, Erasmus MC, Rotterdam, The Netherlands
- Department of Medical Sciences, University Hospital, Uppsala, Sweden
- Department of Tyco Healthcare, Petten, The Netherlands
Peter P.M. Kooij
- Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
- Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
- Department of Hetology, Erasmus MC, Rotterdam, The Netherlands
- Department of Clinical Chemistry, Erasmus MC, Rotterdam, The Netherlands
- Department of Medical Sciences, University Hospital, Uppsala, Sweden
- Department of Tyco Healthcare, Petten, The Netherlands
Pieternella J. Lugtenburg
- Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
- Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
- Department of Hetology, Erasmus MC, Rotterdam, The Netherlands
- Department of Clinical Chemistry, Erasmus MC, Rotterdam, The Netherlands
- Department of Medical Sciences, University Hospital, Uppsala, Sweden
- Department of Tyco Healthcare, Petten, The Netherlands
Frank H. de Jong
- Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
- Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
- Department of Hetology, Erasmus MC, Rotterdam, The Netherlands
- Department of Clinical Chemistry, Erasmus MC, Rotterdam, The Netherlands
- Department of Medical Sciences, University Hospital, Uppsala, Sweden
- Department of Tyco Healthcare, Petten, The Netherlands
Arjan Christiansen
- Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
- Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
- Department of Hetology, Erasmus MC, Rotterdam, The Netherlands
- Department of Clinical Chemistry, Erasmus MC, Rotterdam, The Netherlands
- Department of Medical Sciences, University Hospital, Uppsala, Sweden
- Department of Tyco Healthcare, Petten, The Netherlands
Boen L.R. Kam
- Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
- Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
- Department of Hetology, Erasmus MC, Rotterdam, The Netherlands
- Department of Clinical Chemistry, Erasmus MC, Rotterdam, The Netherlands
- Department of Medical Sciences, University Hospital, Uppsala, Sweden
- Department of Tyco Healthcare, Petten, The Netherlands
Wouter W. de Herder
- Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
- Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
- Department of Hetology, Erasmus MC, Rotterdam, The Netherlands
- Department of Clinical Chemistry, Erasmus MC, Rotterdam, The Netherlands
- Department of Medical Sciences, University Hospital, Uppsala, Sweden
- Department of Tyco Healthcare, Petten, The Netherlands
Mats Stridsberg
- Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
- Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
- Department of Hetology, Erasmus MC, Rotterdam, The Netherlands
- Department of Clinical Chemistry, Erasmus MC, Rotterdam, The Netherlands
- Department of Medical Sciences, University Hospital, Uppsala, Sweden
- Department of Tyco Healthcare, Petten, The Netherlands
Jan Lindemans
- Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
- Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
- Department of Hetology, Erasmus MC, Rotterdam, The Netherlands
- Department of Clinical Chemistry, Erasmus MC, Rotterdam, The Netherlands
- Department of Medical Sciences, University Hospital, Uppsala, Sweden
- Department of Tyco Healthcare, Petten, The Netherlands
Geert Ensing
- Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
- Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
- Department of Hetology, Erasmus MC, Rotterdam, The Netherlands
- Department of Clinical Chemistry, Erasmus MC, Rotterdam, The Netherlands
- Department of Medical Sciences, University Hospital, Uppsala, Sweden
- Department of Tyco Healthcare, Petten, The Netherlands
Eric P. Krenning
- Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
- Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
- Department of Hetology, Erasmus MC, Rotterdam, The Netherlands
- Department of Clinical Chemistry, Erasmus MC, Rotterdam, The Netherlands
- Department of Medical Sciences, University Hospital, Uppsala, Sweden
- Department of Tyco Healthcare, Petten, The Netherlands
- Address reprint requests to Eric P. Krenning, MD, Department of Nuclear Medicine, Erasmus University Centre, Rotterdam, 3015GD Rotterdam, The Netherlands.